By vgreene, 9 July, 2019 KRAS1-3 prognostic; not indicated as routine stand-alone assay as a sole determinant of targeted tx; appropriate to include KRAS as part of larger testing panels performed either initially or when routine EFGR, ALK, BRAF, and ROS1 testing is negative2